JZL184 is primarily used in research settings to study the endocannabinoid system, particularly the role of monoacylglycerol lipase (MAGL) in various physiological processes. By inhibiting MAGL, JZL184 increases the levels of 2-arachidonoylglycerol (2-AG), an endocannabinoid, which helps researchers understand its effects on pain, inflammation, and neurological disorders. It has been instrumental in exploring potential therapeutic strategies for conditions like chronic pain, neurodegenerative diseases, and mood disorders. Additionally, JZL184 is used to investigate the interplay between the endocannabinoid system and other signaling pathways, providing insights into cellular and molecular mechanisms. Its application is limited to preclinical studies, as its safety and efficacy in humans have not been established.